Navigation Links
Depomed Reports Second Quarter 2014 Financial Results
Date:8/6/2014

="prnews_span">$

76,081$

-Total revenues (GAAP Basis)$

67,732$

29,963$

144,277$

56,137(1)
Depomed acquired Lazanda in July 2013 and CAMBIA in December 2013.Selling, general and administrative expense was $32.6 million for the second quarter of 2014 as compared to $25.4 million for the second quarter of 2013. The increase in 2014 is primarily due to increased sales and marketing expenses associated with the Cambia and Lazanda® product acquisitions which occurred in the second half of 2013 and increased legal expense related to ongoing patent infringement litigation.

Research and development expense was $1.4 million for the second quarter of 2014 as compared to $1.4 million for the second quarter of 2013.

GAAP net income for the second quarter of 2014 was $12.7 million, or $0.21 per diluted share, compared to GAAP net income of $0.5 million, or $0.01 per diluted share for the second quarter of 2013.  The increase in GAAP net income resulted primarily from increased product sales and the recognition of non-cash revenue relating to the royalties sold to PDL as described above under the caption "Accounting Treatment for the Sale of Type 2 Diabetes Royalties and Milestones to PDL."

Cash and marketable securities were $223.7 million as of June 30, 2014 as compared to $213.1 million as of March 31, 2014. The increase in cash and marketable securities in the second quarter of 2014 is primarily related to receipt of $15 million in milestone payments from Mallinckrodt during the second quarter of 2014.

2014 F
'/>"/>

SOURCE Depomed, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
2. Depomed To Present At Jefferies 2012 Global Health Care Conference
3. Depomed Announces Filing Of Shelf Registration To Replace Existing Shelf
4. Depomed To Present At JMP Securities 7th Annual Healthcare Conference
5. Depomed To Report Second Quarter Fiscal Year 2012 Financial Results On Thursday, August 2, 2012
6. Depomed To Present At Stifel Nicolaus 2012 Healthcare Conference
7. Depomed To Present At Morgan Stanley 2012 Healthcare Conference
8. Depomed To Present At UBS Global Life Sciences Conference
9. Depomed To Report Third Quarter Fiscal Year 2012 Financial Results On Monday, November 5, 2012
10. Depomed Reports Third Quarter Financial Results
11. Depomed To Present At Lazard 2012 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , July 6, 2015 Moerae Matrix, ... novel therapeutics that target inflammation and fibrosis, today ... M.D., PhD, as Chief Medical Officer. ... development strategy and programs, which include a pipeline ... and fibrotic conditions.  Bill is an accomplished strategist ...
(Date:7/6/2015)... , July 6, 2015 Celtaxsys, Inc., a ... including those with rare and orphan inflammatory disease indications, ... U.S. Food and Drug Administration (FDA) to begin a ... acebilustat (CTX-4430), in adult CF patients in the US. ... Europe will be filed soon after. ...
(Date:7/6/2015)... SUNNYVALE, Calif. , July 6, 2015   ... will report financial results for its 2015 second quarter ... after the close of the market. The ... Pacific Time on Thursday, July 23, 2015, to discuss ... Cepheid,s website at http://ir.cepheid.com at least 15 ...
Breaking Medicine Technology:Moerae Matrix, Inc. (Moerae) Appoints Bill Bradford, M.D., PhD, as Chief Medical Officer 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3
... Calif., March 1, 2012 A consistent theme ... relationship, technological innovation and disease treatment is progression.  ... be seen in healthcare IT, which is expected ... to the healthcare industry.  Companies must maintain a ...
... 1, 2012  In a single bound, Nepean Cancer Care ... for its prostate cancer cases to a dramatically faster ... a technique that is even quicker with Elekta,s new ... treated their first patient with prostate cancer using Integrity ...
Cached Medicine Technology:Frost & Sullivan's Global Healthcare Approach Evolves to Contend with Today's Challenges 2Frost & Sullivan's Global Healthcare Approach Evolves to Contend with Today's Challenges 3Australian Clinic Puts Prostate Cancer Radiation Therapy on Fast Track With Elekta VMAT and Integrity Digital Control System 2Australian Clinic Puts Prostate Cancer Radiation Therapy on Fast Track With Elekta VMAT and Integrity Digital Control System 3
(Date:7/6/2015)... ... July 06, 2015 , ... Human induced pluripotent stem ... are generated from adult cells, such as blood or skin, can replicate indefinitely ... body. , iPSC-derived cardiomyocytes have proven valuable in helping to ...
(Date:7/6/2015)... ... 2015 , ... “ TapGlance ” was featured on NewsWatch as part of ... the market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and ... app helps users visualize what rooms will look like before they even start renovating.. ...
(Date:7/6/2015)... ... , ... June 22, 2015, Fox News in a report titled “ Female Hair Loss Needs to ... a quarter of all women in the U.S. will suffer from thinning hair or hair ... discussed. One woman, a former beauty queen, who was interviewed for the report began losing ...
(Date:7/6/2015)... ... July 06, 2015 , ... Invitation to Cover: , ... is a large gap between the unmet health priorities in the region and ... and reduce unnecessary or ineffective treatments or procedures. , This milestone conference, sponsored ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... Olive Fertility ... the UBC 2014-2015 Post Graduate Teaching Award on behalf of the department of Family ... a very exciting field to be practicing in. The technology is changing so rapidly ...
Breaking Medicine News(10 mins):Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 2Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 3Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 4Health News:Create a Space with TapGlance, a Revolutionary Interior Design Application 2Health News:The Stigma of Female Hair Loss and Hair Restoration Solutions 2Health News:Columbia Nursing Nairobi Summit: Setting a Clinical Research Agenda for Africa 2Health News:Olive Fertility Centre Physician Honoured for Teaching 2
... 20% of recent returnees, but help is available , , ... was known as shell shock. In later military combat ... the emotional scars veterans brought back with them got ... depression, anxiety, substance abuse. , As Americans gather for ...
... Nov. 11 The Grand Opening Celebration of ... 19, from 7:00 until,10:00 p.m. Ocean Blue Plastic ... Miami,s most prestigious addresses. Guests are invited to ... Blue Plastic Surgery while,sampling hors d,oeuvres and sipping ...
... SOUTH PORTLAND, Maine, Nov. 11 Anthem Blue Cross ... nation out of 250 health,insurance plans, according to the ... America,s Best Health Plans 2008. This recognition as one,of ... outstanding overall,performance in clinical care measures, member satisfaction and ...
... 11 In recent independent testing,by ConsumerLab.com ... Plus met standards for ingredient and product ... is available at, http://www.consumerlab.com/results/melatonin.asp ., Schiff ... a sounder,sleep, passed analyses for melatonin and ...
... of, Serious Health Outcomes and Mortality Caused by Fine-Particle ... ... Texas, Nov. 11 A new health impact white paper,conducted by ... at the Harvard School of Public Health,shows that Trane CleanEffects(TM), a ...
... in Patients Increased by 58,Percent From August ... from Arlington,Medical Resources, MALVERN, Pa., Nov. ... of premier market intelligence for the pharmaceutical ... Imaging,s,Cardiolite has 15 percent more market share ...
Cached Medicine News:Health News:Homecoming Veterans Often Face Inner Challenge 2Health News:Homecoming Veterans Often Face Inner Challenge 3Health News:Ocean Blue Plastic Surgery to Open This Month on Brickell Avenue 2Health News:Anthem Blue Cross and Blue Shield in Maine Ranks in Top 6% of all insurers on U.S. News & World Report/National Committee for Quality Assurance Best Health Plans List 2Health News:Anthem Blue Cross and Blue Shield in Maine Ranks in Top 6% of all insurers on U.S. News & World Report/National Committee for Quality Assurance Best Health Plans List 3Health News:Schiff(R) Melatonin Plus Passes ConsumerLab.com Test for Ingredients and Product Quality 2Health News:Schiff(R) Melatonin Plus Passes ConsumerLab.com Test for Ingredients and Product Quality 3Health News:Whole-House Air Cleaner May Help Prevent Asthma Attack, Heart Attack and Stroke 2Health News:Whole-House Air Cleaner May Help Prevent Asthma Attack, Heart Attack and Stroke 3Health News:Radiopharmaceutical Cardiolite has 15 Percent More Market Share than Myoview for September 2008 2
... Microscope with excellent maneuverability. Konan ... weight maintaining high quality. Easy ... by simply changing the adapter. ... has resulted in a sharp ...
... The Optimal temporary implant for use with ... The pupil dilator type 5S is a ... of the pupil during phacoemulsification. It is ... use. Indication: Expansion of the pupil during ...
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
... anatomy of the eyelid for maximum patient ... ease of insertion. Easily removal with forceps. ... offer a slightly smaller bulb for easier ... the same clear and polished silicone as ...
Medicine Products: